PRDM9 and neoplasm: The histone methyltransferase EZH2 is widely recognized as a tumor‐promoting regulatory molecule.[38] Despite the abnormal expression of EZH2 in tumors, EZH2 inhibitors are only effective in limited types of tumors, and clinical trials in most solid tumors appear unsatisfactory.